The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19
Findings indicate that dual inflammation exacerbates the acute phase clinical outcome of COVID-SZs. Suggesting a combined anti-inflammatory drug or the use of potentially anti-inflammatory antipsychotics in the acute phase of treatment to mitigate central nervous system damage. Regular monitoring of inflammatory marker levels can help reduce the risk of fluctuating psychiatric symptoms in patients with schizophrenia caused by inflammatory storms.
Authors
- Peng Wang (ORCID: https://orcid.org/0000-0002-8838-682X)
- Mingqia Wang (ORCID: https://orcid.org/0000-0002-5315-6389)
- Qi Zhou (ORCID: https://orcid.org/0000-0002-4754-4764)
- Zhuokai Zhang
- Xuan Dong (ORCID: https://orcid.org/0000-0002-5853-2136)
- Jiahui Zhu
- Yuan Liu (ORCID: https://orcid.org/0000-0001-9452-0442)
- Zhuoran Li (ORCID: https://orcid.org/0009-0005-7646-4391)
- Chuan Shi (ORCID: https://orcid.org/0000-0002-2627-1189)
- Jiamin Shao
- Gangming Cheng
Institutions
- Capital Medical University (CN)
- University of Toronto (CA)
- Peking University (CN)
- Nanjing Brain Hospital (CN)
- Wuhan No.1 Hospital (CN)
- Beijing Anding Hospital (CN)
- Wuhan No. 7 Hospital (CN)
- Peking University Sixth Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Brain Behavior & Immunity - Health
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1016/j.bbih.2025.101015
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00